1. Home
  2. AMCX vs NERV Comparison

AMCX vs NERV Comparison

Compare AMCX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AMC Networks Inc.

AMCX

AMC Networks Inc.

HOLD

Current Price

$6.74

Market Cap

331.2M

ML Signal

HOLD

Logo Minerva Neurosciences Inc

NERV

Minerva Neurosciences Inc

HOLD

Current Price

$7.70

Market Cap

269.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMCX
NERV
Founded
1980
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Cable & Other Pay Television Services
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
331.2M
269.6M
IPO Year
2011
2014

Fundamental Metrics

Financial Performance
Metric
AMCX
NERV
Price
$6.74
$7.70
Analyst Decision
Sell
Hold
Analyst Count
5
1
Target Price
$7.00
$7.00
AVG Volume (30 Days)
432.4K
194.4K
Earning Date
05-08-2026
03-11-2026
Dividend Yield
N/A
N/A
EPS Growth
132.55
N/A
EPS
1.66
N/A
Revenue
$2,311,801,000.00
$41,175,600.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.06
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.41
$1.15
52 Week High
$10.28
$12.46

Technical Indicators

Market Signals
Indicator
AMCX
NERV
Relative Strength Index (RSI) 33.42 64.59
Support Level $5.69 $5.34
Resistance Level $8.24 $12.46
Average True Range (ATR) 0.36 0.71
MACD -0.12 0.04
Stochastic Oscillator 3.03 70.37

Price Performance

Historical Comparison
AMCX
NERV

About AMCX AMC Networks Inc.

AMC Networks owns several linear pay-TV networks, including AMC, WE tv, BBC America, IFC, and SundanceTV. AMC, its most widely distributed network, reached 60 million pay-TV households in the US at the end of 2024. The firm also had nearly 12.5 million US streaming subscribers, with AMC+ as the flagship streaming platform. With both its linear networks and streaming offerings, the firm caters to specific niche audiences. Over the last 15 years, AMC has shifted its focus to original scripted programming from classic movies. It creates content through AMC Studios and also generates revenue from licensing content. Following an international divestiture at the end of 2023, domestic operations make up nearly 90% of total revenue.

About NERV Minerva Neurosciences Inc

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Share on Social Networks: